GS/MS SF v. CVP SF for Healthcare Investment Banking?

Was wondering if anyone could provide insights on BB (GS/MS) vs. CVP for Healthcare IB in SF. Mainly would love to know about deal experience and exit opportunities. I understand that CVP is dominating sellside biotech M&A deals, but wondering how important it is to get IPO & ECM exposure for the industry. Also heard that recruiting is discouraged and a lot of people end up pursuing PhDs and MDs afterwards. 

1 Comments
 

Sit quis odit delectus tenetur ut. Ipsam reprehenderit rerum quae magni rem. Laboriosam voluptas iure aut natus. Quaerat ut dolorum minima. Optio sed et velit debitis suscipit qui sed.

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Goldman Sachs 01 97.8%
  • Morgan Stanley 07 97.3%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 07 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan No 97.3%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (51) $260
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (26) $182
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”